LAB vs OGN · rev $174.4M vs P/E 3.4, rev $6.40B
Standard Biotools Inc (LAB) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
LAB currently screens at market cap $317.1M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the LAB and OGN stock pages for the full models.
Not investment advice.